Albany NY (PRWEB) December 15, 2012
The global infertility drugs market revenue for the year 2010 was estimated at USD 2,486.7 million and is expected to reach an estimated value of USD 3,352.7 million in 2017, growing at a CAGR of 4.3% from 2012 – 2017. The global infertility devices market revenue was estimated at USD 1,066.7 million in 2010 and is expected to reach an estimated value of USD 1,423.6 million by 2017, growing at a CAGR of 4.2% from 2012 – 2017.
The key growth drivers for infertility drugs and devices market include rising number of infertile people, increasing worldwide obesity and rising disposable incomes of the consumers. Other driving factors include rising number of smokers, increasing stress and pollution, adoption of babies by homosexual couples and the availability of government support for infertility abatement procedures. The global female infertile population seeking medical care was estimated to be 67.5 million in 2010 and the number is estimated to increase to reach 72.3 million by 2017. The number of infertile females opting for artificial insemination though their spouse’s sperm was estimated at 31.4 million in 2010.
The Europe infertility drugs and devices market was estimated at USD 802.8 million in 2010 and is expected to reach an estimated value of USD 952.3 million by 2017, growing at a CAGR of 2.4% from 2012 – 2017. The North America infertility drugs and devices market was estimated at USD 1,382.8 million in 2010 and is expected to reach an estimated value of USD 1,628.5 million by 2017, growing at a CAGR of 2.3% from 2012 – 2017.
The growth of the market is restrained by factors such as limited insurance cover, religious bans on artificial insemination procedures especially Islamic bans, risk of repeat procedures, traditional infertility treatments like the Chinese infertility treatments, ban on artificial reproduction procedures in European region and patent expiration of infertility drugs.
Technological advancements and developmental activities pertaining to healthcare infrastructures especially in the Asia Pacific region, medical tourism initiatives in developing countries and need for more Assisted Reproductive Technologies (ART) cycles act as opportunities fuelling future market growth
The key players dominating the infertility drugs and devices market include Merck, Ferring, Johnson and Johnson, Teva Pharmaceuticals, Origio and Bayer. In 2011, Merck was the market leader with 14% of market share followed by Ferring at 12%.
This research is specially designed to estimate and analyze the demand and performance of Infertility drugs and devices in global scenario. This research provides in-depth analysis of Infertility drugs and device manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global Infertility drugs and devices market and provide in-depth analysis, historical data and statistically refined forecast for the segments covered.